MeSH term
Frequency | Condition_Probility | Cells, Cultured | 17 | 0.0 |
Female | 232 | 0.0 |
Humans | 539 | 0.0 |
Research Support, Non-U.S. Gov't | 305 | 0.0 |
Adult | 212 | 0.0 |
Aged | 83 | 0.0 |
Analysis of Variance | 8 | 0.0 |
Base Sequence | 36 | 0.0 |
Comparative Study | 58 | 0.0 |
Genetic Predisposition to Disease | 3 | 0.0 |
Male | 285 | 0.0 |
Middle Aged | 185 | 0.0 |
Molecular Sequence Data | 47 | 0.0 |
Mutation | 17 | 0.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/analysis/*genetics | 2 | 100.0 |
Polymerase Chain Reaction | 18 | 0.0 |
*Polymorphism, Genetic | 2 | 0.0 |
Probability | 3 | 0.0 |
Prospective Studies | 6 | 0.0 |
Sensitivity and Specificity | 3 | 0.0 |
Binding Sites | 7 | 0.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/*genetics | 24 | 96.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
Amino Acid Sequence | 34 | 0.0 |
Amino Acids/chemistry | 2 | 1.0 |
Enzyme Activation | 26 | 0.0 |
Lipoproteins, HDL/blood/chemistry/*metabolism | 2 | 66.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/metabolism | 28 | 50.0 |
Research Support, U.S. Gov't, P.H.S. | 141 | 0.0 |
Sequence Homology, Amino Acid | 5 | 0.0 |
Lipoproteins, HDL/*blood | 41 | 21.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/*blood | 105 | 93.0 |
*Renal Dialysis | 7 | 1.0 |
Time Factors | 29 | 0.0 |
Triglycerides/blood | 88 | 6.0 |
Animals | 107 | 0.0 |
Apolipoprotein A-I/*metabolism | 4 | 9.0 |
Blotting, Western | 7 | 0.0 |
English Abstract | 50 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Mice | 38 | 0.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/*biosynthesis/genetics | 2 | 100.0 |
Transfection | 16 | 0.0 |
Risk Factors | 19 | 0.0 |
Acylation | 3 | 4.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/*metabolism | 45 | 86.0 |
Thiobarbituric Acid Reactive Substances/analysis | 2 | 9.0 |
Epitopes/*immunology | 2 | 0.0 |
Lipoproteins/blood/chemistry | 4 | 36.0 |
Aryldialkylphosphatase | 3 | 1.0 |
Kinetics | 41 | 0.0 |
Lipids/blood | 48 | 7.0 |
Mice, Transgenic | 22 | 0.0 |
RNA, Messenger/analysis | 3 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 27 | 0.0 |
Transcription, Genetic | 3 | 0.0 |
Biological Markers/blood | 5 | 0.0 |
Cholesterol/metabolism | 24 | 8.0 |
Esterification | 35 | 42.0 |
Apolipoprotein A-I/*genetics/metabolism | 3 | 30.0 |
Pedigree | 39 | 0.0 |
Thiobarbituric Acid Reactive Substances/metabolism | 2 | 4.0 |
Erythrocytes/metabolism | 3 | 1.0 |
Reference Values | 25 | 0.0 |
Renal Dialysis | 3 | 0.0 |
Apolipoprotein A-I/chemistry/genetics/*metabolism | 3 | 60.0 |
Mutagenesis, Site-Directed | 13 | 0.0 |
Mutation/genetics | 2 | 0.0 |
Particle Size | 22 | 7.0 |
Protein Structure, Tertiary | 4 | 0.0 |
Spectrometry, Fluorescence | 10 | 2.0 |
*Glycoproteins | 55 | 6.0 |
Lipids/*blood | 34 | 5.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/*blood/genetics | 2 | 100.0 |
Polymorphism, Genetic | 4 | 0.0 |
Apolipoproteins/blood | 37 | 16.0 |
Fibroblasts | 2 | 0.0 |
Lecithin Acyltransferase Deficiency/*blood/genetics | 6 | 100.0 |
Lipoproteins/blood | 55 | 13.0 |
Phenotype | 13 | 0.0 |
Point Mutation | 7 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 3 | 0.0 |
Apolipoprotein A-I/metabolism | 13 | 17.0 |
Circular Dichroism | 10 | 2.0 |
Dimyristoylphosphatidylcholine/metabolism | 3 | 37.0 |
Fibroblasts/metabolism | 8 | 0.0 |
Lipoproteins/*metabolism | 5 | 3.0 |
Lipoproteins, HDL/*metabolism | 17 | 14.0 |
Recombinant Proteins/metabolism | 6 | 0.0 |
Microscopy, Electron | 22 | 1.0 |
Acute-Phase Reaction/*blood | 2 | 7.0 |
Biological Transport | 15 | 1.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/blood | 51 | 70.0 |
*Phospholipid Transfer Proteins | 13 | 8.0 |
Ultracentrifugation | 17 | 8.0 |
Amino Acid Substitution | 3 | 0.0 |
Apolipoprotein A-I/blood | 11 | 10.0 |
Electrophoresis, Polyacrylamide Gel | 28 | 0.0 |
Heterozygote | 18 | 0.0 |
Lipoproteins, HDL Cholesterol/blood | 42 | 6.0 |
Restriction Mapping | 8 | 0.0 |
Sequence Analysis, DNA | 7 | 0.0 |
Carrier Proteins/*blood | 25 | 10.0 |
Child | 23 | 0.0 |
Child, Preschool | 14 | 0.0 |
Cholesterol/*blood | 24 | 9.0 |
Cholesterol Esters/*blood | 30 | 36.0 |
Diabetes Mellitus, Type 1/*blood/enzymology | 2 | 66.0 |
Fasting | 4 | 1.0 |
Lipoproteins, LDL Cholesterol/blood | 21 | 3.0 |
Genes, Recessive | 3 | 0.0 |
Phosphatidylcholines/metabolism | 9 | 9.0 |
Rats | 30 | 0.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Insulin/*pharmacology | 2 | 0.0 |
Insulin Resistance | 2 | 1.0 |
Lipids/blood/*metabolism | 3 | 16.0 |
Lipoproteins/metabolism | 6 | 5.0 |
Liver/drug effects/metabolism | 2 | 2.0 |
Disease Models, Animal | 4 | 0.0 |
Alleles | 6 | 0.0 |
Kidney/ultrastructure | 2 | 25.0 |
*Mutation | 9 | 0.0 |
Lipid Peroxidation | 4 | 3.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/*antagonists & inhibitors | 6 | 75.0 |
Biopsy | 4 | 0.0 |
Kidney/pathology | 4 | 2.0 |
Arteriosclerosis/metabolism | 2 | 3.0 |
Cell Line | 19 | 0.0 |
Cholesterol/*metabolism | 17 | 6.0 |
Dose-Response Relationship, Drug | 8 | 0.0 |
Hamsters | 13 | 0.0 |
Macrophages/metabolism | 2 | 0.0 |
Mesocricetus | 3 | 1.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/*physiology | 3 | 60.0 |
*Gene Deletion | 3 | 0.0 |
Lipoproteins, HDL Cholesterol/*blood | 27 | 12.0 |
Precipitin Tests | 2 | 0.0 |
Substrate Specificity | 19 | 0.0 |
Abetalipoproteinemia/*blood | 2 | 50.0 |
Adolescent | 47 | 0.0 |
Apolipoproteins B/*blood | 3 | 1.0 |
Lipoproteins/*blood | 64 | 10.0 |
Lipoproteins, HDL/blood | 38 | 14.0 |
Lipoproteins, LDL/blood | 28 | 11.0 |
Arginine | 3 | 3.0 |
Finland | 5 | 1.0 |
Gene Transfer Techniques | 3 | 0.0 |
Hypolipoproteinemia/*genetics | 25 | 80.0 |
Mice, Inbred C57BL | 9 | 0.0 |
Mice, Knockout | 5 | 0.0 |
*Variation (Genetics) | 3 | 0.0 |
*Protein Conformation | 2 | 0.0 |
Sequence Alignment | 5 | 0.0 |
Diabetes Mellitus, Type 2/*blood | 5 | 4.0 |
Infant, Newborn | 9 | 0.0 |
Pregnancy | 5 | 0.0 |
Apolipoprotein A-II/*blood | 2 | 33.0 |
Case-Control Studies | 6 | 0.0 |
1-Alkyl-2-acetylglycerophosphocholine Esterase | 3 | 12.0 |
Dithionitrobenzoic Acid/pharmacology | 5 | 10.0 |
In Vitro | 14 | 0.0 |
*Plants, Toxic | 4 | 10.0 |
*Smoke | 4 | 28.0 |
Sulfhydryl Reagents/pharmacology | 2 | 4.0 |
*Tobacco | 4 | 17.0 |
Electrostatics | 3 | 2.0 |
Enzyme Activation/drug effects | 8 | 0.0 |
Models, Molecular | 7 | 0.0 |
Phospholipids/metabolism | 5 | 2.0 |
Protein Binding | 14 | 0.0 |
Gene Expression/physiology | 2 | 0.0 |
Lipoproteins, HDL/genetics/*metabolism | 4 | 57.0 |
Cholesterol/blood | 94 | 7.0 |
Longitudinal Studies | 2 | 0.0 |
Renal Dialysis/*adverse effects | 2 | 1.0 |
Triglycerides/analysis/blood | 2 | 40.0 |
Biological Markers | 3 | 0.0 |
Carrier Proteins/blood | 12 | 11.0 |
Insulin/blood | 3 | 0.0 |
Lipase/blood | 9 | 12.0 |
Lipoprotein Lipase/blood | 9 | 11.0 |
Treatment Outcome | 2 | 0.0 |
Lipoproteins, LDL Cholesterol/*blood | 3 | 3.0 |
Membrane Proteins/blood | 5 | 12.0 |
Lipoprotein Lipase/*deficiency | 2 | 18.0 |
Lymph/*chemistry | 2 | 50.0 |
Apolipoprotein A-II/metabolism | 4 | 28.0 |
Carrier Proteins/metabolism | 7 | 0.0 |
Glycoproteins/metabolism | 2 | 1.0 |
Lipoproteins, HDL Cholesterol/*metabolism | 5 | 13.0 |
Aorta/pathology | 3 | 7.0 |
Arteriosclerosis/*prevention & control | 2 | 11.0 |
Diet | 7 | 1.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/genetics/*physiology | 2 | 100.0 |
Lipoproteins, VLDL Cholesterol/blood | 4 | 6.0 |
Lipids/metabolism | 12 | 3.0 |
Liver/*metabolism | 3 | 0.0 |
RNA, Messenger/metabolism | 4 | 0.0 |
Structure-Activity Relationship | 16 | 0.0 |
RNA, Messenger/biosynthesis | 4 | 0.0 |
Rabbits | 18 | 0.0 |
Lipoproteins/chemistry | 2 | 16.0 |
Protein Conformation | 17 | 0.0 |
Apolipoprotein A-I/*chemistry/metabolism | 3 | 75.0 |
Lipoproteins, HDL/metabolism | 7 | 6.0 |
Protein Structure, Secondary | 8 | 0.0 |
Apolipoprotein A-I/chemistry/*metabolism | 4 | 57.0 |
Apolipoproteins A/metabolism | 5 | 29.0 |
Cholesterol Esters/*metabolism | 5 | 5.0 |
Chromatography, High Pressure Liquid | 7 | 0.0 |
Protein Denaturation | 4 | 1.0 |
Sequence Deletion | 2 | 0.0 |
Lipoproteins, LDL/metabolism | 8 | 3.0 |
Spectrum Analysis, Mass | 3 | 0.0 |
*Membrane Fluidity | 2 | 8.0 |
Body Mass Index | 6 | 0.0 |
Gene Expression | 6 | 0.0 |
Glycosylation | 2 | 0.0 |
Liver/*enzymology | 6 | 1.0 |
Plasmids | 3 | 0.0 |
Recombinant Proteins/chemistry/metabolism | 5 | 0.0 |
Sequence Analysis | 3 | 0.0 |
Tumor Cells, Cultured | 3 | 0.0 |
Amino Acid Sequence/genetics | 2 | 0.0 |
Apolipoprotein A-I/blood/*genetics | 3 | 33.0 |
Genotype | 7 | 0.0 |
Apolipoproteins B/blood | 13 | 5.0 |
Birth Weight | 2 | 1.0 |
Gestational Age | 5 | 0.0 |
Lipoproteins/blood/*metabolism | 3 | 9.0 |
Obesity/*metabolism | 2 | 2.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/analysis | 3 | 75.0 |
Hypolipoproteinemia/*metabolism | 3 | 60.0 |
Regression Analysis | 4 | 0.0 |
Phosphatidylcholines/blood | 13 | 59.0 |
Phospholipids/blood | 30 | 22.0 |
Sterol O-Acyltransferase/blood | 4 | 57.0 |
*Gene Expression | 3 | 0.0 |
Gene Therapy | 3 | 0.0 |
DNA Mutational Analysis | 4 | 0.0 |
Electrophoresis, Agar Gel | 8 | 1.0 |
Gene Deletion | 3 | 0.0 |
Aged, 80 and over | 5 | 0.0 |
Apolipoprotein A-I/analysis | 2 | 10.0 |
Gene Expression/genetics | 2 | 0.0 |
Lecithin Acyltransferase Deficiency/blood/*genetics | 9 | 100.0 |
Syndrome | 9 | 0.0 |
*Genes, Structural | 5 | 0.0 |
Protein Biosynthesis | 3 | 0.0 |
Lipoprotein Lipase/*blood | 7 | 6.0 |
Lipoproteins, VLDL/blood | 24 | 10.0 |
Drug Combinations | 3 | 0.0 |
Infusions, Intravenous | 2 | 0.0 |
Membrane Proteins/*blood | 3 | 5.0 |
Phosphatidylcholines/*blood | 5 | 33.0 |
Anticholesteremic Agents/*therapeutic use | 2 | 3.0 |
Follow-Up Studies | 2 | 0.0 |
Hypercholesterolemia/blood/*drug therapy | 2 | 8.0 |
*Kidney Transplantation | 4 | 0.0 |
Probucol/*therapeutic use | 4 | 33.0 |
Cholesterol Esters/metabolism | 13 | 11.0 |
Lecithin Acyltransferase Deficiency/*blood | 9 | 81.0 |
Lipoproteins, HDL/isolation & purification | 2 | 50.0 |
Oxidation-Reduction | 8 | 0.0 |
Phospholipases A/metabolism | 2 | 3.0 |
Lipoproteins, LDL/*metabolism | 6 | 3.0 |
Antioxidants/*metabolism | 3 | 3.0 |
Lipids/*metabolism | 3 | 1.0 |
Fluorescent Antibody Technique | 3 | 0.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/genetics/metabolism | 2 | 40.0 |
Phosphatidylcholines/*metabolism | 6 | 12.0 |
Lipase/chemistry | 2 | 100.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/*chemistry | 2 | 100.0 |
Cholesterol/blood/*metabolism | 3 | 13.0 |
Electrophoresis, Gel, Two-Dimensional/methods | 2 | 9.0 |
Lipoproteins, HDL/*blood/chemistry | 3 | 27.0 |
Phospholipids/*blood | 3 | 9.0 |
Statistics | 3 | 0.0 |
*Point Mutation | 7 | 0.0 |
Hela Cells | 2 | 0.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/physiology | 2 | 100.0 |
Cross-Over Studies | 3 | 0.0 |
Glycoproteins/blood | 3 | 5.0 |
Sex Factors | 3 | 0.0 |
Triglycerides/metabolism | 5 | 3.0 |
Apolipoprotein A-I/*blood | 6 | 18.0 |
Cohort Studies | 4 | 0.0 |
Dietary Fats/*administration & dosage | 3 | 3.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/blood/*metabolism | 5 | 100.0 |
Cross-Sectional Studies | 2 | 0.0 |
*Estrogen Replacement Therapy | 3 | 2.0 |
Apolipoprotein A-I/*chemistry/genetics/physiology | 2 | 100.0 |
Enzyme Activation/genetics | 2 | 2.0 |
Recombinant Proteins/biosynthesis/metabolism | 2 | 1.0 |
Tritium | 3 | 1.0 |
Centrifugation, Density Gradient | 5 | 1.0 |
Cholesterol Esters/blood | 49 | 40.0 |
Chromatography, Gas | 5 | 5.0 |
Phospholipids/blood/chemistry | 3 | 60.0 |
Species Specificity | 10 | 0.0 |
Fatty Acids, Nonesterified/blood | 6 | 3.0 |
Liver/enzymology | 15 | 2.0 |
Heparin | 4 | 5.0 |
Lipase/*blood | 5 | 8.0 |
Smoking/*blood | 3 | 12.0 |
Alcohol Drinking/*blood | 2 | 14.0 |
*Postprandial Period | 2 | 6.0 |
Triglycerides/*blood | 11 | 3.0 |
Animals, Genetically Modified | 4 | 1.0 |
DNA Primers/genetics | 2 | 0.0 |
Homozygote | 11 | 0.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/*blood/*genetics | 2 | 100.0 |
Hydrolysis | 4 | 0.0 |
Electrophoresis, Gel, Two-Dimensional | 6 | 1.0 |
Enzyme Activation/physiology | 2 | 1.0 |
Immunoblotting | 5 | 0.0 |
Drug Therapy, Combination | 2 | 0.0 |
Apolipoproteins E/*blood | 3 | 5.0 |
Blood Glucose/analysis | 5 | 0.0 |
C-Peptide/blood | 2 | 1.0 |
Proteolipids/metabolism | 6 | 25.0 |
Stereoisomerism | 2 | 0.0 |
Cholesterol/*pharmacokinetics | 2 | 66.0 |
*Gene Therapy | 3 | 0.0 |
DNA/genetics | 5 | 0.0 |
*Introns | 2 | 0.0 |
Models, Biological | 3 | 0.0 |
CHO Cells | 3 | 0.0 |
Phospholipids/*metabolism | 4 | 3.0 |
Apolipoprotein A-I/*chemistry | 3 | 37.0 |
Lipoproteins, HDL/*chemistry | 6 | 35.0 |
Surface Properties | 3 | 1.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/*chemistry/genetics | 2 | 100.0 |
Recombinant Proteins/chemistry | 2 | 0.0 |
Arginine/genetics | 2 | 1.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/*genetics/metabolism | 4 | 100.0 |
Catalysis | 2 | 0.0 |
Histidine | 2 | 4.0 |
Apolipoprotein A-I/*deficiency/*genetics | 2 | 66.0 |
*Homozygote | 2 | 1.0 |
Mutation/*genetics | 4 | 0.0 |
Estradiol/blood | 2 | 0.0 |
Horses | 2 | 1.0 |
*Postmenopause | 2 | 3.0 |
Phospholipases A/*metabolism | 2 | 4.0 |
Apolipoproteins/*blood | 10 | 6.0 |
Chromatography, Gel | 8 | 0.0 |
Lipase/metabolism | 4 | 7.0 |
COS Cells | 3 | 0.0 |
Cercopithecus aethiops | 2 | 0.0 |
Cholesterol/blood/metabolism | 4 | 21.0 |
*Diet, Atherogenic | 2 | 22.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/genetics/*metabolism | 5 | 100.0 |
Apolipoprotein A-II/blood | 4 | 21.0 |
Dimerization | 2 | 0.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/blood/*genetics | 6 | 100.0 |
Lecithin Acyltransferase Deficiency/metabolism | 2 | 66.0 |
Lipoproteins/pharmacology | 2 | 9.0 |
Arteriosclerosis/etiology | 4 | 5.0 |
Cloning, Molecular | 6 | 0.0 |
Corneal Opacity/*genetics | 4 | 66.0 |
Polymorphism, Restriction Fragment Length | 4 | 0.0 |
Molecular Weight | 9 | 0.0 |
Isoelectric Focusing | 2 | 0.0 |
Lipoproteins, HDL/blood/*metabolism | 4 | 36.0 |
Tangier Disease/*blood | 3 | 50.0 |
Phosphatidylcholines/*chemistry/metabolism | 2 | 100.0 |
Liver/metabolism | 7 | 0.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/genetics | 8 | 72.0 |
RNA, Messenger/genetics | 4 | 0.0 |
Infant, Small for Gestational Age/*blood | 2 | 66.0 |
Sterol O-Acyltransferase/*blood | 8 | 100.0 |
DNA/chemistry | 2 | 0.0 |
Polymorphism, Single-Stranded Conformational | 2 | 0.0 |
Osmolar Concentration | 6 | 0.0 |
Apolipoproteins E/blood | 4 | 8.0 |
Lecithin Acyltransferase Deficiency/*etiology | 2 | 100.0 |
Densitometry | 4 | 2.0 |
Lecithin Acyltransferase Deficiency/*genetics | 19 | 100.0 |
Cholesterol Esters/biosynthesis | 2 | 14.0 |
1-Acylglycerophosphocholine O-Acyltransferase/*blood | 4 | 80.0 |
Lipoproteins | 2 | 33.0 |
Electrophoresis | 6 | 2.0 |
Lipoproteins, HDL Cholesterol/blood/genetics | 2 | 15.0 |
*Chromosome Mapping | 4 | 0.0 |
DNA, Complementary | 4 | 0.0 |
*Multigene Family | 2 | 0.0 |
Swine | 7 | 0.0 |
Double-Blind Method | 6 | 0.0 |
Enzyme Inhibitors/*pharmacology | 2 | 0.0 |
Simvastatin | 2 | 6.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/*analysis | 2 | 100.0 |
Apolipoprotein A-I/blood/genetics | 2 | 33.0 |
Carcinoma, Hepatocellular | 3 | 0.0 |
Fatty Acids/analysis | 5 | 17.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/*biosynthesis/blood/genetics | 3 | 100.0 |
Acute Disease | 5 | 0.0 |
Hypertension/*blood/enzymology | 2 | 33.0 |
Infant | 5 | 0.0 |
Carrier Proteins/*metabolism | 4 | 0.0 |
Triglycerides/*metabolism | 2 | 2.0 |
Blood Proteins/analysis | 2 | 1.0 |
Immunodiffusion | 8 | 3.0 |
Immunoelectrophoresis | 8 | 3.0 |
Drug Administration Schedule | 2 | 0.0 |
Blotting, Northern | 3 | 0.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/biosynthesis/*metabolism | 2 | 100.0 |
Skin/metabolism | 2 | 1.0 |
Lecithin Acyltransferase Deficiency/blood | 6 | 100.0 |
Apolipoprotein A-I/chemistry | 2 | 25.0 |
Chemical Fractionation | 2 | 2.0 |
Copper/metabolism | 2 | 3.0 |
Cross-Linking Reagents | 2 | 0.0 |
Evaluation Studies | 4 | 0.0 |
Lipoproteins, LDL/*pharmacology | 3 | 5.0 |
Models, Structural | 2 | 1.0 |
Age Factors | 3 | 0.0 |
Alcohol Drinking/epidemiology | 2 | 10.0 |
Japan/epidemiology | 2 | 0.0 |
Smoking/epidemiology | 2 | 3.0 |
Cholesterol Esters/blood/*metabolism | 2 | 25.0 |
Hemoglobin A, Glycosylated/analysis | 3 | 0.0 |
Apolipoproteins C/blood | 2 | 6.0 |
Heterozygote Detection | 2 | 0.0 |
Lecithin Acyltransferase Deficiency/*blood/enzymology | 2 | 100.0 |
Gemfibrozil/administration & dosage/*therapeutic use | 2 | 100.0 |
Hyperlipidemia/*blood | 2 | 5.0 |
Proteolipids | 4 | 40.0 |
Sterol O-Acyltransferase/metabolism | 4 | 21.0 |
Apolipoproteins A/blood | 3 | 4.0 |
*Lipolysis | 3 | 10.0 |
*Parenteral Nutrition, Total | 3 | 5.0 |
Mice, Inbred Strains | 2 | 0.0 |
Membrane Fluidity | 3 | 8.0 |
*Exons | 4 | 1.0 |
Blood Glucose/*metabolism | 3 | 1.0 |
Diabetes Mellitus/blood/enzymology | 3 | 100.0 |
DNA, Complementary/genetics | 2 | 0.0 |
*Gene Expression Regulation, Enzymologic | 2 | 0.0 |
Lipoproteins, HDL/blood/*deficiency | 2 | 100.0 |
*Mutagenesis, Site-Directed | 3 | 3.0 |
Lecithin Acyltransferase Deficiency/complications/*genetics | 3 | 100.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/chemistry/*genetics | 2 | 66.0 |
Phosphatidylcholines/pharmacology | 2 | 10.0 |
Apolipoproteins A/*blood | 7 | 15.0 |
Infant, Premature/*blood | 3 | 9.0 |
Lipoproteins, LDL/*blood | 8 | 5.0 |
Multivariate Analysis | 2 | 0.0 |
Radioimmunoassay | 5 | 0.0 |
Apolipoprotein A-I/*pharmacology | 2 | 22.0 |
Sterol O-Acyltransferase/*metabolism | 5 | 71.0 |
Carrier Proteins/pharmacology | 2 | 3.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/pharmacology | 2 | 100.0 |
*Chromosomes, Human, Pair 16 | 6 | 2.0 |
Anemia/etiology | 2 | 6.0 |
Corneal Opacity/etiology | 3 | 75.0 |
Corneal Opacity/genetics | 6 | 66.0 |
Cattle | 2 | 0.0 |
Chromosomes, Human, Pair 16 | 2 | 1.0 |
Haptoglobins/genetics | 3 | 6.0 |
1-Acylglycerophosphocholine O-Acyltransferase/metabolism | 2 | 100.0 |
Acyltransferases/*metabolism | 2 | 16.0 |
Apolipoproteins/metabolism | 2 | 5.0 |
Lysophosphatidylcholines/pharmacology | 2 | 11.0 |
Nephrotic Syndrome/*metabolism | 2 | 50.0 |
Serum Albumin/pharmacology | 2 | 5.0 |
Apoproteins/blood | 4 | 21.0 |
Macrophages/*metabolism | 2 | 0.0 |
Platelet Activating Factor/*metabolism | 3 | 15.0 |
Coronary Angiography | 2 | 0.0 |
Apolipoproteins/analysis | 4 | 14.0 |
Apolipoproteins A/*analysis | 2 | 20.0 |
Uric Acid/blood | 3 | 5.0 |
Apolipoproteins/*metabolism | 2 | 5.0 |
Lipase/*metabolism | 3 | 5.0 |
Lipoprotein Lipase/*metabolism | 4 | 2.0 |
Apolipoproteins/analysis/*metabolism | 2 | 66.0 |
Creatinine/blood | 2 | 0.0 |
Proteinuria | 2 | 5.0 |
Radioisotope Dilution Technique | 2 | 6.0 |
Chemistry, Physical | 4 | 2.0 |
Apolipoproteins | 2 | 50.0 |
Chromosome Mapping | 2 | 0.0 |
Hyperlipoproteinemia/*blood | 2 | 8.0 |
Plasma | 2 | 3.0 |
Lipoproteins/*blood/isolation & purification | 2 | 33.0 |
Serum Albumin/metabolism | 3 | 1.0 |
Apolipoproteins C/*pharmacology | 2 | 40.0 |
Cholesterol | 5 | 50.0 |
Lipoproteins, LDL/*blood/chemistry | 2 | 10.0 |
*Alleles | 4 | 0.0 |
Apolipoproteins A/*chemistry/metabolism | 2 | 100.0 |
Liver Diseases/*blood | 3 | 9.0 |
DNA Probes | 3 | 0.0 |
Proteinuria/genetics | 3 | 23.0 |
Lipoproteins, VLDL/*blood | 2 | 2.0 |
Sterol O-Acyltransferase/*deficiency | 2 | 100.0 |
Liposomes | 4 | 1.0 |
Lecithin Acyltransferase Deficiency/genetics/*metabolism | 3 | 100.0 |
*Diet, Reducing | 3 | 4.0 |
Lipoprotein Lipase/metabolism | 3 | 2.0 |
Lecithin Acyltransferase Deficiency/blood/*genetics/pathology | 2 | 100.0 |
Liver Transplantation/*physiology | 2 | 10.0 |
Prognosis | 6 | 0.0 |
*Tissue Donors | 2 | 1.0 |
Immune Sera | 6 | 2.0 |
DNA/blood/genetics/isolation & purification | 2 | 5.0 |
Oligodeoxyribonucleotides | 3 | 0.0 |
Rats, Inbred Strains | 4 | 0.0 |
Lecithin Acyltransferase Deficiency/blood/enzymology/*genetics | 3 | 100.0 |
Polymerase Chain Reaction/methods | 2 | 0.0 |
Antibodies, Monoclonal | 3 | 0.0 |
Liver Neoplasms | 2 | 0.0 |
Erythrocyte Membrane/*metabolism | 2 | 2.0 |
Lecithin Acyltransferase Deficiency/blood/*complications | 2 | 100.0 |
Cholesterol/analysis | 3 | 6.0 |
Leukocytes/enzymology | 2 | 1.0 |
Fat Emulsions, Intravenous/*pharmacology | 2 | 16.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/*blood/metabolism | 4 | 100.0 |
Thermodynamics | 2 | 0.0 |
Apolipoprotein A-I | 21 | 18.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/blood/*physiology | 2 | 100.0 |
Sphingomyelins/blood | 3 | 60.0 |
Exercise/*physiology | 2 | 0.0 |
Blood Pressure | 3 | 0.0 |
Biological Markers/*blood | 2 | 1.0 |
Enzyme Tests | 2 | 2.0 |
Precipitation | 2 | 1.0 |
Sex Characteristics | 2 | 0.0 |
Liver Cirrhosis/*blood | 2 | 5.0 |
Sequence Homology, Nucleic Acid | 5 | 0.0 |
Liver Function Tests | 5 | 2.0 |
*Liver Transplantation | 2 | 1.0 |
Blood Pressure/*drug effects | 2 | 1.0 |
Food, Formulated | 2 | 6.0 |
Lipoproteins, LDL/pharmacology | 2 | 4.0 |
Lipoproteins, VLDL/pharmacology | 4 | 25.0 |
Transplantation, Homologous | 2 | 0.0 |
Apolipoproteins E/metabolism | 2 | 3.0 |
Hypolipoproteinemia/*enzymology | 4 | 100.0 |
Carrier Proteins/blood/*metabolism | 2 | 9.0 |
Aging | 3 | 0.0 |
Dialysis | 2 | 4.0 |
Acyltransferases/*blood | 13 | 92.0 |
Phosphatidylethanolamines/blood | 2 | 20.0 |
Liver/pathology | 2 | 1.0 |
Apolipoprotein A-II | 6 | 12.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/blood/metabolism | 2 | 100.0 |
Chemistry | 7 | 3.0 |
Erythrocytes/*metabolism | 3 | 1.0 |
Contraceptives, Oral/pharmacology | 2 | 11.0 |
Chromatography, Affinity | 3 | 0.0 |
Propranolol/pharmacology | 3 | 6.0 |
Serum Albumin/analysis | 2 | 1.0 |
Corneal Stroma/pathology | 3 | 60.0 |
Hypolipoproteinemia/*complications | 3 | 75.0 |
Binding, Competitive | 2 | 0.0 |
Hypolipoproteinemia/*blood | 14 | 63.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/*blood/immunology | 2 | 100.0 |
Tangier Disease/*blood/enzymology | 2 | 66.0 |
Hypercholesterolemia, Familial/*blood | 3 | 17.0 |
Hyperlipoproteinemia Type IV/*blood | 3 | 25.0 |
Hypercholesterolemia, Familial/blood | 2 | 12.0 |
Coronary Disease/*blood/enzymology | 2 | 50.0 |
Apolipoproteins A/*genetics | 2 | 4.0 |
Amino Acids/analysis | 2 | 0.0 |
Apolipoproteins/*pharmacology | 2 | 33.0 |
Apolipoproteins A/*pharmacology | 2 | 40.0 |
*Liposomes | 2 | 5.0 |
Phosphatidylcholines | 8 | 23.0 |
Abetalipoproteinemia/*enzymology | 2 | 100.0 |
Norway | 3 | 2.0 |
Fatty Acids/blood | 3 | 6.0 |
Lipid Metabolism, Inborn Errors/*blood | 2 | 100.0 |
Body Weight | 6 | 0.0 |
*Exertion | 3 | 1.0 |
Temperature | 3 | 0.0 |
Chronic Disease | 5 | 0.0 |
Cholestasis/*enzymology | 2 | 100.0 |
Liver Diseases/*enzymology/metabolism | 2 | 66.0 |
Kidney/*pathology | 2 | 3.0 |
Lecithin Acyltransferase Deficiency/*genetics/pathology | 4 | 100.0 |
Pregnadienes/*pharmacology | 2 | 28.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/antagonists & inhibitors | 2 | 100.0 |
Membrane Proteins/blood/metabolism | 2 | 50.0 |
Aerobiosis | 2 | 8.0 |
Diagnosis, Differential | 4 | 0.0 |
Lipoproteins, VLDL Cholesterol | 3 | 23.0 |
Lipids/analysis | 2 | 4.0 |
Phospholipases A | 2 | 50.0 |
Keratoplasty, Penetrating | 2 | 15.0 |
Consanguinity | 3 | 0.0 |
Hyperlipidemia/blood | 2 | 5.0 |
*Blood Pressure | 2 | 1.0 |
Docosahexaenoic Acids | 2 | 66.0 |
*Fishes | 2 | 18.0 |
Propanolamines/pharmacology | 2 | 25.0 |
Chromatography, Thin Layer | 5 | 3.0 |
Fat Emulsions, Intravenous | 2 | 40.0 |
Bile Acids and Salts/blood | 2 | 25.0 |
Oxygen Consumption | 2 | 0.0 |
Phospholipids/analysis | 2 | 5.0 |
Triglycerides/analysis | 2 | 6.0 |
Hyperlipidemia/blood/enzymology | 2 | 100.0 |
Lipoprotein-X/*blood | 2 | 66.0 |
Fat Emulsions, Intravenous/*administration & dosage | 2 | 33.0 |
Lipoproteins, HDL Cholesterol | 10 | 21.0 |
Lipoproteins, LDL Cholesterol | 7 | 28.0 |
Triiodothyronine/blood | 2 | 0.0 |
Apoproteins/*blood | 2 | 15.0 |
Arteriosclerosis/*etiology/metabolism | 2 | 33.0 |
Blood Platelets/metabolism | 2 | 1.0 |
Calcinosis/etiology | 2 | 33.0 |
Collagen/metabolism | 2 | 0.0 |
Diabetes Mellitus/metabolism | 2 | 5.0 |
Elastin/metabolism | 2 | 13.0 |
Hypertension/etiology | 2 | 4.0 |
Magnesium/*metabolism | 2 | 10.0 |
Magnesium Deficiency/complications | 2 | 50.0 |
Muscle, Smooth, Vascular/metabolism | 2 | 3.0 |
Potassium/*metabolism | 2 | 4.0 |
Potassium Deficiency/complications | 2 | 100.0 |
Thrombosis/etiology | 2 | 3.0 |
*Dietary Fats | 2 | 9.0 |
Eicosapentaenoic Acid | 2 | 66.0 |
Apolipoproteins B | 2 | 4.0 |
Diabetes Mellitus/*blood/enzymology | 2 | 100.0 |
Health Surveys | 2 | 2.0 |
Carrier Proteins/*genetics | 2 | 0.0 |
Diabetes Mellitus/blood | 2 | 2.0 |
Japan | 2 | 0.0 |
Heat | 3 | 0.0 |
Lysophosphatidylcholines/blood | 5 | 62.0 |
Lipoproteins, HDL/*blood/isolation & purification | 2 | 20.0 |
Erythrocytes/*drug effects | 2 | 9.0 |
Phospholipids/*analysis | 2 | 13.0 |
Hypertension/blood/enzymology | 2 | 100.0 |
Obesity/blood/enzymology | 2 | 66.0 |
Risk | 2 | 0.0 |
Heterozygote Detection/*methods | 2 | 3.0 |
Phosphatidylcholine-Sterol O-Acyltransferase/immunology | 2 | 100.0 |
Lecithin Acyltransferase Deficiency | 2 | 100.0 |
Phosphatidylcholines/*pharmacology | 2 | 18.0 |
Anemia/genetics | 2 | 40.0 |
Erythrocytes/*analysis | 2 | 4.0 |
Amino Acids/blood | 2 | 4.0 |
Immunologic Techniques | 2 | 0.0 |
Liver Diseases/*enzymology | 3 | 23.0 |
*Lecithin Acyltransferase Deficiency | 6 | 100.0 |
Methods | 5 | 2.0 |
Heparin/pharmacology | 2 | 0.0 |
Liver Diseases/enzymology | 2 | 25.0 |
Foam Cells/pathology | 2 | 22.0 |
Coronary Disease/epidemiology | 2 | 10.0 |
Acyltransferases/*deficiency | 6 | 66.0 |
Lipid Metabolism, Inborn Errors/*blood/genetics | 2 | 66.0 |
